Next-generation sequencers market will reach $5.1 billion in 2033, forecasts GlobalData

With decreased test fees, GlobalData anticipates that the demand for routine diagnostic procedures, including cancer panel testing and non-invasive prenatal testing, will grow

0
72
New Delhi: Next-generation sequencing (NGS) has revolutionized the in vitro diagnostics (IVD) market by providing enhanced diagnostic capabilities and expanding the market scope.
The next-generation sequencers market is poised to grow at a compound annual growth rate (CAGR) of 10.3% from $1.9 billion in 2023 to $5.1 billion in 2033, forecasts GlobalData, a leading data and analytics company.
GlobalData’s latest report, “Next Generation Sequencers Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033,” visualizes quantitative market trends within IVD therapeutic area.
Tina Deng, MSc, Principal Medical Devices Analyst at GlobalData, comments: “The NGS market’s growth is fuelled by a combination of unaddressed clinical needs for more effective tools in predicting, diagnosing, treating, and monitoring diseases, along with the ongoing advancement of sequencing technologies for efficiency. During the forecast period, revenue is expected to be primarily generated by high-throughput and medium-throughput NGS.”
NGS allows for the simultaneous sequencing of millions of fragments to generate a large amount of data in a single run, saving time and resources. Additionally, the cost of sequencing has significantly reduced with the advent of NGS, as it allows for the sequencing of large amounts of DNA or RNA much more quickly than the previously used Sanger sequencing.
Deng concludes: “With decreased test fees, GlobalData anticipates that the demand for routine diagnostic procedures, including cancer panel testing and non-invasive prenatal testing, will grow.”